See What HealthDay Can Do For You
Contact Us

In Complicated UTI, Cefiderocol Noninferior to Imipenem-Cilastin

Results from phase 2 study in patients with multidrug-resistant Gram-negative uropathogens

intravenous drip

MONDAY, Oct. 29, 2018 (HealthDay News) -- For complicated urinary tract infections caused by multidrug-resistant Gram-negative uropathogens, the siderophore cephalosporin cefiderocol is non-inferior to imipenem-cilastatin, according to a study published online Oct. 25 in The Lancet Infectious Diseases.

Simon Portsmouth, M.D., from Shionogi Inc., in Florham Park, New Jersey, and colleagues conducted a phase 2 non-inferiority trial at 67 hospitals in 15 countries. A total of 452 patients admitted to the hospital with a clinical diagnosis of complicated urinary tract infection with or without pyelonephritis or with acute uncomplicated pyelonephritis were randomized to intravenous infusions of cefiderocol or imipenem-cilastatin every eight hours for seven to 14 days; 300 and 148 patients, respectively, received treatment. A total of 252 patients in the cefiderocol group and 119 patients in the imipenem-cilastatin group had a qualifying Gram-negative uropathogen and were included in the analysis of the primary end point of a composite of clinical and microbiological outcomes seven days after cessation of treatment.

The researchers found that 73 and 55 percent of patients in the cefiderocol and imipenem-cilastatin groups, respectively, achieved the primary efficacy end point, with an adjusted treatment difference of 18.58 percent, establishing the noninferiority of cefiderocol. The patients tolerated cefiderocol well; adverse events occurred in 41 and 51 percent of patients in the cefiderocol and imipenem-cilastatin groups, respectively.

"As a siderophore antibiotic, cefiderocol is a novel approach that might be used to overcome Gram-negative resistance," the authors write.

The authors disclosed ties to Shionogi & Co. Ltd. and Shionogi Inc., which funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.